Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 3/20 | 0.44 |
| ▸ | RECQL | P46063 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | BLM | P54132 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | GLB1 | P16278 | 1/20 | 0.44 |
| ▸ | CTRC | Q99895 | 1/20 | 0.44 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.36 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18171688 | 0.86 | ALDH1A1 (0.44) | THRBRECQLTDP1MEN1KMT2A | |
| SCHEMBL204164 | 0.85 | ALDH1A1 (0.48) | THRBRECQLTDP1MEN1KMT2A | |
| SCHEMBL202598 | 0.85 | ALDH1A1 (0.48) | THRBRECQLTDP1MEN1KMT2A | |
| SCHEMBL5508223 | 0.78 | SMAD3 (0.38) | THRBRECQLTDP1MEN1KMT2A | |
| SCHEMBL37698 | 0.76 | HPGD (0.54) | THRBRECQLTDP1MEN1KMT2A | |
| SCHEMBL6823049 | 0.75 | RECQL (0.43) | THRBRECQLTDP1MEN1KMT2A | |
| SCHEMBL203192 | 0.75 | GNG2 (0.43) | THRBRECQLTDP1MEN1KMT2A | |
| SCHEMBL347626 | 0.75 | THRB (0.50) | THRBRECQLTDP1MEN1KMT2A | |
| SCHEMBL5094500 | 0.74 | THRB (0.41) | THRBRECQLTDP1MEN1KMT2A | |
| SCHEMBL29486978 | 0.74 | MEN1 (0.61) | THRBRECQLTDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1711825-A4 | CONJUGATED SMALL MOLECULES | AMBIT BIOSCIENCES CORP (US) | 2008-01-23 | — | — | EP | claimed |
| JP-2007521338-A | — | — | 2007-08-02 | — | — | JP | claimed |
| EP-1711825-A2 | CONJUGATED SMALL MOLECULES | Ambit Biosciences Corporation (US) | 2006-10-18 | — | — | EP | claimed |
| WO-2005067644-A2 | CONJUGATED SMALL MOLECULES | AMBIT BIOSCIENCES CORPORATION (US) | 2005-07-28 | — | — | WO | claimed |
| US-20050153371-A1 | Conjugated small molecules | AMBIT BIOSCIENCES CORPORATION | 2005-07-14 | — | — | US | claimed |
| US-20100048890-A1 | CONJUGATED SMALL MOLECULES | DISCOVERX CORPORATION | 2010-02-25 | — | — | US | disclosed |
| EP-1109935-B1 | TWO-COLOUR DIFFERENTIAL DISPLAY, USED AS A METHOD FOR DETECTING REGULATED GENES | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-02-20 | — | — | EP | disclosed |
| EP-1711825-A4 | CONJUGATED SMALL MOLECULES | AMBIT BIOSCIENCES CORP (US) | 2008-01-23 | — | — | EP | disclosed |
| EP-1711825-A2 | CONJUGATED SMALL MOLECULES | Ambit Biosciences Corporation (US) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005067644-A2 | CONJUGATED SMALL MOLECULES | AMBIT BIOSCIENCES CORPORATION (US) | 2005-07-28 | — | — | WO | disclosed |
| US-20050153371-A1 | Conjugated small molecules | AMBIT BIOSCIENCES CORPORATION | 2005-07-14 | — | — | US | disclosed |
| US-6645741-B2 | Screening nucleotide sequences samples; obtain nucleotide sequences, incubate with primers, amplify nucleotide sequences, analyzing amplified nucleotide sequences | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-11-11 | — | — | US | disclosed |
| US-20020090636-A1 | Screening nucleotide sequences samples; obtain nucleotide sequences, incubate with primers, amplify nucleotide sequences, analyzing amplified nucleotide sequences | AVENTIS PHARMA DEUTSCHLAND GMBH. | 2002-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048890-A1 | CONJUGATED SMALL MOLECULES | ERBB2, ALK, ACP1 | THRB 2854/4885RECQL 4449/4885TDP1 3880/4885 |
| US-20050153371-A1 | Conjugated small molecules | ERBB2, ALK, ACP1 | THRB 2854/4885RECQL 4449/4885TDP1 3880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.